| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 产品(元) | - | - | 155,242,967.70 | - | 123,707,361.24 |
| 服务(元) | - | 53,980,579.48 | 22,272,053.76 | 52,555,588.37 | 19,667,857.64 |
| 293培养基(元) | - | 22,751,938.90 | - | 17,522,084.15 | - |
| CHO培养基(元) | - | 261,072,304.73 | - | 198,929,274.87 | - |
| CDMO(元) | 23,768,601.84 | - | - | - | - |
| 实验动物销售(元) | 12,087,160.00 | - | - | - | - |
| 细胞培养产品收入(元) | 208,021,129.45 | - | - | - | - |
| 药物临床前CRO服务(元) | 181,969,513.74 | - | - | - | - |
| 医疗器械临床前CRO服务(元) | 20,641,646.91 | - | - | - | - |
| 租赁收入及相关服务(元) | 7,201,956.14 | - | - | - | - |
| 其他(元) | - | 16,630,711.24 | - | 27,769,107.58 | - |
| 营业成本(元) | |||||
| 产品(元) | - | - | 43,604,752.73 | - | 36,696,886.40 |
| 服务(元) | - | 81,724,243.33 | 32,858,725.72 | 65,844,276.83 | 20,555,913.53 |
| 293培养基(元) | - | 9,150,801.03 | - | 4,940,733.50 | - |
| CHO培养基(元) | - | 70,366,108.14 | - | 54,889,953.96 | - |
| CDMO(元) | 35,537,259.02 | - | - | - | - |
| 实验动物销售(元) | 7,363,610.04 | - | - | - | - |
| 细胞培养产品收入(元) | 66,967,602.55 | - | - | - | - |
| 药物临床前CRO服务(元) | 109,952,771.68 | - | - | - | - |
| 医疗器械临床前CRO服务(元) | 18,139,482.71 | - | - | - | - |
| 租赁收入及相关服务(元) | 6,810,540.17 | - | - | - | - |
| 其他(元) | - | 12,707,871.32 | - | 13,454,874.89 | - |
| 毛利(元) | |||||
| 产品(元) | - | - | 111,638,214.97 | - | 87,010,474.84 |
| 服务(元) | - | -27,743,663.85 | -10,586,671.96 | -13,288,688.46 | -888,055.89 |
| 293培养基(元) | - | 13,601,137.87 | - | 12,581,350.65 | - |
| CHO培养基(元) | - | 190,706,196.59 | - | 144,039,320.91 | - |
| CDMO(元) | -11,768,657.18 | - | - | - | - |
| 实验动物销售(元) | 4,723,549.96 | - | - | - | - |
| 细胞培养产品收入(元) | 141,053,526.90 | - | - | - | - |
| 药物临床前CRO服务(元) | 72,016,742.06 | - | - | - | - |
| 医疗器械临床前CRO服务(元) | 2,502,164.20 | - | - | - | - |
| 租赁收入及相关服务(元) | 391,415.97 | - | - | - | - |
| 其他(元) | - | 3,922,839.92 | - | 14,314,232.69 | - |
| 毛利率(%) | |||||
| 产品(%) | - | - | 71.91 | - | 70.34 |
| 服务(%) | - | -51.40 | -47.53 | -25.29 | -4.52 |
| 293培养基(%) | - | 59.78 | - | 71.80 | - |
| CHO培养基(%) | - | 73.05 | - | 72.41 | - |
| CDMO(%) | -49.51 | - | - | - | - |
| 实验动物销售(%) | 39.08 | - | - | - | - |
| 细胞培养产品收入(%) | 67.81 | - | - | - | - |
| 药物临床前CRO服务(%) | 39.58 | - | - | - | - |
| 医疗器械临床前CRO服务(%) | 12.12 | - | - | - | - |
| 租赁收入及相关服务(%) | 5.43 | - | - | - | - |
| 其他(%) | - | 23.59 | - | 51.55 | - |
| 收入构成(%) | |||||
| 产品(%) | - | - | 87.45 | - | 86.28 |
| 服务(%) | - | 15.23 | 12.55 | 17.71 | 13.72 |
| 293培养基(%) | - | 6.42 | - | 5.90 | - |
| CHO培养基(%) | - | 73.66 | - | 67.03 | - |
| CDMO(%) | 5.24 | - | - | - | - |
| 实验动物销售(%) | 2.66 | - | - | - | - |
| 细胞培养产品收入(%) | 45.85 | - | - | - | - |
| 药物临床前CRO服务(%) | 40.11 | - | - | - | - |
| 医疗器械临床前CRO服务(%) | 4.55 | - | - | - | - |
| 租赁收入及相关服务(%) | 1.59 | - | - | - | - |
| 其他(%) | - | 4.69 | - | 9.36 | - |
| 毛利构成(%) | |||||
| 产品(%) | - | - | 110.48 | - | 101.03 |
| 服务(%) | - | -15.37 | -10.48 | -8.43 | -1.03 |
| 293培养基(%) | - | 7.54 | - | 7.98 | - |
| CHO培养基(%) | - | 105.66 | - | 91.37 | - |
| CDMO(%) | -5.63 | - | - | - | - |
| 实验动物销售(%) | 2.26 | - | - | - | - |
| 细胞培养产品收入(%) | 67.52 | - | - | - | - |
| 药物临床前CRO服务(%) | 34.47 | - | - | - | - |
| 医疗器械临床前CRO服务(%) | 1.20 | - | - | - | - |
| 租赁收入及相关服务(%) | 0.19 | - | - | - | - |
| 其他(%) | - | 2.17 | - | 9.08 | - |